1. Home
  2. PCRX vs DHC Comparison

PCRX vs DHC Comparison

Compare PCRX & DHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • DHC
  • Stock Information
  • Founded
  • PCRX 2006
  • DHC 1998
  • Country
  • PCRX United States
  • DHC United States
  • Employees
  • PCRX N/A
  • DHC N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • DHC Real Estate Investment Trusts
  • Sector
  • PCRX Health Care
  • DHC Real Estate
  • Exchange
  • PCRX Nasdaq
  • DHC Nasdaq
  • Market Cap
  • PCRX 1.2B
  • DHC 757.5M
  • IPO Year
  • PCRX 2011
  • DHC N/A
  • Fundamental
  • Price
  • PCRX $23.22
  • DHC $3.75
  • Analyst Decision
  • PCRX Buy
  • DHC Hold
  • Analyst Count
  • PCRX 8
  • DHC 3
  • Target Price
  • PCRX $28.38
  • DHC $4.50
  • AVG Volume (30 Days)
  • PCRX 569.8K
  • DHC 962.0K
  • Earning Date
  • PCRX 07-29-2025
  • DHC 07-31-2025
  • Dividend Yield
  • PCRX N/A
  • DHC 1.07%
  • EPS Growth
  • PCRX N/A
  • DHC N/A
  • EPS
  • PCRX N/A
  • DHC N/A
  • Revenue
  • PCRX $702,772,000.00
  • DHC $1,511,515,000.00
  • Revenue This Year
  • PCRX $7.54
  • DHC $3.98
  • Revenue Next Year
  • PCRX $10.78
  • DHC $4.50
  • P/E Ratio
  • PCRX N/A
  • DHC N/A
  • Revenue Growth
  • PCRX 3.08
  • DHC 5.33
  • 52 Week Low
  • PCRX $11.16
  • DHC $2.00
  • 52 Week High
  • PCRX $27.64
  • DHC $4.24
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 35.42
  • DHC 67.68
  • Support Level
  • PCRX $22.82
  • DHC $3.50
  • Resistance Level
  • PCRX $24.36
  • DHC $3.82
  • Average True Range (ATR)
  • PCRX 0.69
  • DHC 0.17
  • MACD
  • PCRX -0.12
  • DHC -0.01
  • Stochastic Oscillator
  • PCRX 17.09
  • DHC 72.55

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About DHC Diversified Healthcare Trust of Beneficial Interest

Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. It operates through two segments: Office Portfolio and SHOP. The office portfolio includes medical office properties leased to medical-related businesses and life sciences properties. The SHOP segment runs communities that offer multiple types of residential care, ranging from independent living to nursing services. DHT operates across the United States and the majority of its revenue derives from rents and medical programs. Majority of revenue is from SHOP segment.

Share on Social Networks: